HERCEPTIN(R) ADJUNCT THERAPY

摘要

PROBLEM TO BE SOLVED: To provide more effective therapy for subjects with non-metastatic breast cancer.SOLUTION: The invention concerns to the results obtained in clinical studies on the adjunct use of HERCEPTIN(R) in human subjects with non-metastatic, high risk breast cancer. The invention provides a method of adjunct therapy, which method comprises administering to a human subject with non-metastatic HER2 positive breast cancer after the definitive surgery thereof, an effective amount of an antibody that binds to HER2 domain IV to which trastuzumab (HERCEPTIN(R)) binds and at least one chemotherapeutic agent, so as to elongate disease-free survival (DFS) or overall survival (OS) in the subject, where the DFS or the OS is evaluated about 2 to 5 years after the start of the treatment.